Similar results were also obtained in a study with 109 Spanish patients diagnosed with moderate-to-severe psoriasis and treated with anti-TNF drugs; TNF-857 rs1799724-C patients had better BSA (83.1% vs. 92.7%, p = 0.004) and PASI (82.7% vs. 92.6%, p = 0.009) scores and better response at 6 months (PASI 75:71.4% vs. 96.3%, p = 0.006) [47]. Here, TNF is linked to psoriasis.